VistaGen Therapeutics (NASDAQ:VTGN) Stock Price Crosses Below Fifty Day Moving Average – Here’s What Happened

VistaGen Therapeutics, Inc. (NASDAQ:VTGN)’s share price crossed below its 50 day moving average during trading on Thursday . The stock has a 50 day moving average of $0.60 and traded as low as $0.55. VistaGen Therapeutics shares last traded at $0.5756, with a volume of 292,642 shares.

Wall Street Analyst Weigh In

Separately, Wall Street Zen downgraded VistaGen Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, March 21st. Four investment analysts have rated the stock with a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company has a consensus rating of “Reduce” and a consensus target price of $0.95.

VistaGen Therapeutics Trading Up 2.8%

The firm has a market cap of $22.81 million, a price-to-earnings ratio of -0.30 and a beta of 0.31. The stock has a fifty day moving average price of $0.60 and a 200 day moving average price of $1.20.

Institutional Trading of VistaGen Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in VTGN. Virtu Financial LLC acquired a new stake in VistaGen Therapeutics in the 4th quarter valued at approximately $25,000. Cubist Systematic Strategies LLC bought a new position in shares of VistaGen Therapeutics during the 1st quarter worth approximately $25,000. Schonfeld Strategic Advisors LLC bought a new position in shares of VistaGen Therapeutics during the 3rd quarter worth approximately $39,000. Seven Fleet Capital Management LP bought a new position in VistaGen Therapeutics in the 4th quarter valued at $42,000. Finally, Tudor Investment Corp ET AL bought a new position in VistaGen Therapeutics in the 4th quarter valued at $50,000. Institutional investors and hedge funds own 78.39% of the company’s stock.

About VistaGen Therapeutics

VistaGen Therapeutics, Inc (NASDAQ:VTGN) is a clinical-stage biopharmaceutical company dedicated to the discovery and development of next-generation medicines for central nervous system disorders. Incorporated in Delaware in 1998 and headquartered in South San Francisco, California, VistaGen applies advanced human pluripotent stem cell technologies to accelerate drug candidate validation and optimization. The company’s core focus is on addressing unmet medical needs in major depressive disorder, neuropathic pain and dermatological conditions.

The company’s lead candidate, AV-101, is an oral prodrug designed to modulate glutamatergic neurotransmission via the N-methyl-D-aspartate (NMDA) receptor pathway, with clinical programs targeting major depressive disorder and neuropathic pain.